Stability of mitomycin C in different infusion fluids: Compatibility with heparin and glucocorticosteroids

Robert T Dorr, James D. Liddil

Research output: Contribution to journalArticle

Abstract

Introduction: Mitomycin C (Mutamycin) stability and compatibility was analyzed by reverse-phase high performance liquid chromatography (HPLC). Methods: The drug was reconstituted in sterile water for injection USP, 0.9% sodium chloride for injection USP, 5% dextrose injection USP and lactated Ringer's injection USP. Samples were stored for vari ous times at —20°C, 4°C and 25°C in both glass and plastic (polyvinyl chloride) containers. Results: Mitomycin C was shown to be stable (> 90% remaining for 5 to 7 days at room temperature in nondextrose containing infusion fluids. Greater stability was noted at drug concentrations ≥ 0.4 μg/mL and at reduced temperatures. In 5% dextrose solutions, stability was highly dependent upon pH: 3.4 hours at pH 4.7 and slightly over 24 hours at pH 5.5. Non-linear decomposition in dextrose was due to a slow increase in solution pH after adding mitomycin C. There were no stability differences for glass or plastic containers. Mitomycin was shown to be stable for prolonged periods when mixed with dexametha sone sodium phosphate (T 90% > 2 days), with hydro cortisone sodium succinate (T90% > 7 days) or with sodium heparin (T 90% > 2 days). Within these times, the concentrations of corticosteroids (measured by HPLC) and heparin (measured by bioassay) did not significantly decline. Conclusions: Mitomycin C demonstrates pro longed stability in nonacidic infusion fluids. Long- term storage in dextrose-containing solutions should be avoided, but short-term admixture with heparin and corticosteroids is feasible.

Original languageEnglish (US)
Pages (from-to)19-24
Number of pages6
JournalJournal of Oncology Pharmacy Practice
Volume1
Issue number3
DOIs
StatePublished - 1995

Fingerprint

Mitomycin
Heparin
Glucose
Injections
Plastics
Glass
Adrenal Cortex Hormones
High Pressure Liquid Chromatography
Temperature
Cortisone
Succinic Acid
Reverse-Phase Chromatography
Prednisone
Polyvinyl Chloride
Sodium Chloride
Biological Assay
Pharmaceutical Preparations
Sodium
Water

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Stability of mitomycin C in different infusion fluids : Compatibility with heparin and glucocorticosteroids. / Dorr, Robert T; Liddil, James D.

In: Journal of Oncology Pharmacy Practice, Vol. 1, No. 3, 1995, p. 19-24.

Research output: Contribution to journalArticle

@article{9a491b35d5924a7480eba1e2f510e869,
title = "Stability of mitomycin C in different infusion fluids: Compatibility with heparin and glucocorticosteroids",
abstract = "Introduction: Mitomycin C (Mutamycin) stability and compatibility was analyzed by reverse-phase high performance liquid chromatography (HPLC). Methods: The drug was reconstituted in sterile water for injection USP, 0.9{\%} sodium chloride for injection USP, 5{\%} dextrose injection USP and lactated Ringer's injection USP. Samples were stored for vari ous times at —20°C, 4°C and 25°C in both glass and plastic (polyvinyl chloride) containers. Results: Mitomycin C was shown to be stable (> 90{\%} remaining for 5 to 7 days at room temperature in nondextrose containing infusion fluids. Greater stability was noted at drug concentrations ≥ 0.4 μg/mL and at reduced temperatures. In 5{\%} dextrose solutions, stability was highly dependent upon pH: 3.4 hours at pH 4.7 and slightly over 24 hours at pH 5.5. Non-linear decomposition in dextrose was due to a slow increase in solution pH after adding mitomycin C. There were no stability differences for glass or plastic containers. Mitomycin was shown to be stable for prolonged periods when mixed with dexametha sone sodium phosphate (T 90{\%} > 2 days), with hydro cortisone sodium succinate (T90{\%} > 7 days) or with sodium heparin (T 90{\%} > 2 days). Within these times, the concentrations of corticosteroids (measured by HPLC) and heparin (measured by bioassay) did not significantly decline. Conclusions: Mitomycin C demonstrates pro longed stability in nonacidic infusion fluids. Long- term storage in dextrose-containing solutions should be avoided, but short-term admixture with heparin and corticosteroids is feasible.",
author = "Dorr, {Robert T} and Liddil, {James D.}",
year = "1995",
doi = "10.1177/107815529500100304",
language = "English (US)",
volume = "1",
pages = "19--24",
journal = "Journal of Oncology Pharmacy Practice",
issn = "1078-1552",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Stability of mitomycin C in different infusion fluids

T2 - Compatibility with heparin and glucocorticosteroids

AU - Dorr, Robert T

AU - Liddil, James D.

PY - 1995

Y1 - 1995

N2 - Introduction: Mitomycin C (Mutamycin) stability and compatibility was analyzed by reverse-phase high performance liquid chromatography (HPLC). Methods: The drug was reconstituted in sterile water for injection USP, 0.9% sodium chloride for injection USP, 5% dextrose injection USP and lactated Ringer's injection USP. Samples were stored for vari ous times at —20°C, 4°C and 25°C in both glass and plastic (polyvinyl chloride) containers. Results: Mitomycin C was shown to be stable (> 90% remaining for 5 to 7 days at room temperature in nondextrose containing infusion fluids. Greater stability was noted at drug concentrations ≥ 0.4 μg/mL and at reduced temperatures. In 5% dextrose solutions, stability was highly dependent upon pH: 3.4 hours at pH 4.7 and slightly over 24 hours at pH 5.5. Non-linear decomposition in dextrose was due to a slow increase in solution pH after adding mitomycin C. There were no stability differences for glass or plastic containers. Mitomycin was shown to be stable for prolonged periods when mixed with dexametha sone sodium phosphate (T 90% > 2 days), with hydro cortisone sodium succinate (T90% > 7 days) or with sodium heparin (T 90% > 2 days). Within these times, the concentrations of corticosteroids (measured by HPLC) and heparin (measured by bioassay) did not significantly decline. Conclusions: Mitomycin C demonstrates pro longed stability in nonacidic infusion fluids. Long- term storage in dextrose-containing solutions should be avoided, but short-term admixture with heparin and corticosteroids is feasible.

AB - Introduction: Mitomycin C (Mutamycin) stability and compatibility was analyzed by reverse-phase high performance liquid chromatography (HPLC). Methods: The drug was reconstituted in sterile water for injection USP, 0.9% sodium chloride for injection USP, 5% dextrose injection USP and lactated Ringer's injection USP. Samples were stored for vari ous times at —20°C, 4°C and 25°C in both glass and plastic (polyvinyl chloride) containers. Results: Mitomycin C was shown to be stable (> 90% remaining for 5 to 7 days at room temperature in nondextrose containing infusion fluids. Greater stability was noted at drug concentrations ≥ 0.4 μg/mL and at reduced temperatures. In 5% dextrose solutions, stability was highly dependent upon pH: 3.4 hours at pH 4.7 and slightly over 24 hours at pH 5.5. Non-linear decomposition in dextrose was due to a slow increase in solution pH after adding mitomycin C. There were no stability differences for glass or plastic containers. Mitomycin was shown to be stable for prolonged periods when mixed with dexametha sone sodium phosphate (T 90% > 2 days), with hydro cortisone sodium succinate (T90% > 7 days) or with sodium heparin (T 90% > 2 days). Within these times, the concentrations of corticosteroids (measured by HPLC) and heparin (measured by bioassay) did not significantly decline. Conclusions: Mitomycin C demonstrates pro longed stability in nonacidic infusion fluids. Long- term storage in dextrose-containing solutions should be avoided, but short-term admixture with heparin and corticosteroids is feasible.

UR - http://www.scopus.com/inward/record.url?scp=84970390297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84970390297&partnerID=8YFLogxK

U2 - 10.1177/107815529500100304

DO - 10.1177/107815529500100304

M3 - Article

AN - SCOPUS:84970390297

VL - 1

SP - 19

EP - 24

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

SN - 1078-1552

IS - 3

ER -